MORRISTOWN, N.J. — Sanofi US announced today a significant expansion of its Insulins Valyou Savings Program, pledging that no American will pay more than $35 per month for any of the company’s insulin products. The program, effective January 1, 2026, will be available to all patients in the United States with a valid prescription, regardless of insurance status.
Initially designed for individuals without health insurance, the Insulins Valyou program now also extends to those with commercial insurance and Medicare coverage, reflecting Sanofi’s broader commitment to addressing the affordability crisis in diabetes care.
“Our announcement builds on an idea first championed by President Trump to lower costs for American patients at the pharmacy counter. At Sanofi, we share his objective and believe that no one should struggle to afford their insulin and we are proud to take this next step as we play our part to keep America healthy,” said Adam Gluck, Head of US Corporate Affairs, Sanofi. “By expanding our Insulins Valyou Savings Program, we're taking concrete action to address a critical healthcare issue for millions of Americans living with diabetes. We will continue to work with policymakers and stakeholders across the healthcare system on additional sustainable, long-term solutions to improve access to medicines.”
The program is available at most U.S. pharmacies, including independent and rural locations, with minimal enrollment requirements. Patients will be able to purchase any combination, type, or quantity of Sanofi insulins for a flat monthly fee of $35.
“Diabetes management requires consistent access to medication, and financial barriers can lead to rationing or skipping doses, which can have serious health consequences,” said Olivier Bogillot, Head of General Medicines, North America, Sanofi. “This program expansion emphasizes our continued support for America's diabetes community.”
The move aligns Sanofi with growing public and political pressure to reduce drug prices and follows similar steps by peers in the pharmaceutical industry. The company emphasized that while the initiative provides immediate relief, it also remains committed to working with policymakers on long-term solutions for equitable access to medicines.
The expanded Insulins Valyou Savings Program will be available to patients beginning January 1, 2026. Patients can enroll at Sanofi Patient Connection or by calling 1-888-847-4877.
